|
9 Companies |
|
8 Products |
|
8 Products |
|
4 Mechanisms of Action |
|
1 Trial |
|
58 News |
|
| «12 |
- | Cubicin (daptomycin) / Merck (MSD)
Enrollment change: Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (clinicaltrials.gov) - Jun 28, 2012
P3, N=194, Terminated, Sponsor: Novartis Pharmaceuticals
N=280 --> 194
- |||||| aztreonam / Generic mfg., vancomycin / Generic mfg., ceftaroline fosamil / Generic mfg.
Enrollment open: Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections (clinicaltrials.gov) - Jun 5, 2012
P3, N=765, Recruiting, Sponsor: AstraZeneca
N=280 --> 194 Not yet recruiting --> Recruiting
- Nuzyra (omadacycline) / Paratek
Trial withdrawal: Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (clinicaltrials.gov) - May 7, 2012
P3, N=0, Withdrawn, Sponsor: Paratek Pharmaceuticals Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Nuzyra (omadacycline) / Paratek
Enrollment change: Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (clinicaltrials.gov) - May 7, 2012
P3, N=0, Withdrawn, Sponsor: Paratek Pharmaceuticals Inc
Not yet recruiting --> Withdrawn N=789 --> 0
- ||||||| Trial completion: Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections (clinicaltrials.gov) - Mar 21, 2012
P3, N=120, Completed, Sponsor: Novartis Pharmaceuticals
N=789 --> 0 Active, not recruiting --> Completed
- New P1 trial: Soft Tissue Ultrasound of Infections (clinicaltrials.gov) - Mar 15, 2012
P1, N=15, Recruiting, Sponsor: Rhode Island Hospital
- |||||||||| aztreonam / Generic mfg., vancomycin / Generic mfg., ceftaroline fosamil / Generic mfg.
New P3 trial: Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections (clinicaltrials.gov) - Dec 22, 2011
P3, N=765, Recruiting, Sponsor: AstraZeneca
- Invanz (ertapenem) / Merck (MSD)
Trial completion: Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection (clinicaltrials.gov) - Aug 7, 2011
P4, N=10, Completed, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Recruiting --> Completed